| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL1017 | Name | NUTF2P3 | Aliases | NUTF2P3-001 | |
| Species | Homo sapiens | Chromosome | 9 | Start site | 77580245 | |
| End site | 77580628 | Chain | plus | Exon NO. | N/A | |
| Assembly | Ensembl Release 89 | Class | N/A | NCBI accession | N/A | |
| Ensembl | ENSG00000228248 | Sequence | N/A | |||
| Function (not disease relevant) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Methods | Sample/condition | Expression pattern | Dysfunction type | Description | PMID | Source | |||
| N/A | N/A | up-regulated | interaction | After downregulating lncRNA-NUTF2P3-001, the proliferation and invasion of pancreatic cancer cell are significantly inhibited both in vitro and vivo, accompanying with decreased KRAS expression. Data from pancreatic cancer patients show a positive correlation between lncRNA-NUTF2P3-001 and KRAS, which is associated with advanced tumor stage and worse prognosis. lncRNA-NUTF2P3-001 and miR-3923 can be applied as novel predictors and therapeutic targets for pancreatic cancer. | 26755660 | ||||
| Interaction | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
| KRAS | RNA-RNA | co-expression | Microarray co-assay for lncRNAs and mRNAs demonstrates that lncRNA-NUTF2P3-001 is remarkably overexpressed in pancreatic cancer and chronic pancreatitis tissues, which positively correlates with KRAS mRNA expression. | 26755660 | |||||
| miR-3923 | RNA-RNA | binding | The dual-luciferase reporter assay further validates that lncRNA-NUTF2P3-001 and 3'UTR of KRAS mRNA competitively bind with miR-3923. | 26755660 | |||||